Editorial Contributions & Industry Insights

As an international key opinion leader with extensive experience in the healthcare ecosystem, I have been at the forefront of shaping industry discussions and policy. Since 2018, I have contributed to PharmaBoardroom, offering in-depth analysis and insights on emerging trends, regulatory changes, and strategic developments within the global healthcare landscape. My work is grounded in a deep understanding of the industry's complexities, making me a trusted voice for stakeholders across the healthcare spectrum.

Read More Here

Featured Posts

Blog
Why We Must Treat Fentanyl as a Chemical Threat — and What Strategic Action Looks Like
Fentanyl, pharmaceutical-grade chemical weapons, opioid-based chemical agents, emerging chemical threat detection, national security, Opioid epidemic, Public health and opioids, Federal response to fentanyl, Fentanyl crisis, Fentanyl trafficking, Law enforcement fentanyl, Chemical industry fentanyl, chemical weapons policy
Why We Must Treat Fentanyl as a Chemical Threat — and What Strategic Action Looks Like
Fentanyl, pharmaceutical-grade chemical weapons, opioid-based chemical agents, emerging chemical threat detection, national security, Opioid epidemic, Public health and opioids, Federal response to fentanyl, Fentanyl crisis, Fentanyl trafficking, Law enforcement fentanyl, Chemical industry fentanyl, chemical weapons policy

Fentanyl has rightly been framed as a public health emergency. But that framing alone is no longer sufficient.

Illicit fentanyl now sits at the intersection of public health, national security, and chemical threat preparedness. Its extreme potency, ease of synthesis, and global availability create a dual-use risk that adversaries could exploit far beyond traditional drug trafficking. Former Department of Defense officials have already warned that terrorist groups may one day attempt to aerosolize fentanyl or its analogues—an alarming prospect with real historical precedent.

In 2002, an aerosolized fentanyl-based compound was used during the Moscow theater hostage crisis, killing more than 130 civilians. Today, similar compounds are more accessible, more potent, and embedded in illicit supply chains that span the globe. The question is no longer whether this risk exists—but whether our preparedness frameworks are aligned to confront it.

Treating fentanyl as a potential chemical threat does not criminalize medicine or undermine addiction treatment. It strengthens deterrence, improves readiness, and ensures that medical countermeasures, detection technologies, and defense doctrine keep pace with evolving threats.

Preparedness is not panic. It is policy maturity.

The full article outlines what strategic action looks like—from modernizing medical countermeasure development to investing in detection and deterrence technologies and leading international norms that close dangerous legal gaps.

Fentanyl, pharmaceutical-grade chemical weapons, opioid-based chemical agents, emerging chemical threat detection, national security, Opioid epidemic, Public health and opioids, Federal response to fentanyl, Fentanyl crisis, Fentanyl trafficking, Law enforcement fentanyl, Chemical industry fentanyl, chemical weapons policy
Fentanyl: From Public Health Crisis to National Security Threat
Fentanyl distribution methods, U.S. opioid supply, International drug control, Law enforcement fentanyl, Overdose antidotes, Regulatory incentives for industry, Biotech innovation overdose, Chemical industry fentanyl, Corporate responsibility opioids, Public health and opioids, Addiction treatment strategies, Financial targeting drug cartels, Supply-chain disruption, Precursor chemicals, Drug cartels, Weapons of mass destruction, Fentanyl trafficking, Federal response to fentanyl, Opioid epidemic, Synthetic opioids, Fentanyl crisis
Fentanyl: From Public Health Crisis to National Security Threat
Fentanyl distribution methods, U.S. opioid supply, International drug control, Law enforcement fentanyl, Overdose antidotes, Regulatory incentives for industry, Biotech innovation overdose, Chemical industry fentanyl, Corporate responsibility opioids, Public health and opioids, Addiction treatment strategies, Financial targeting drug cartels, Supply-chain disruption, Precursor chemicals, Drug cartels, Weapons of mass destruction, Fentanyl trafficking, Federal response to fentanyl, Opioid epidemic, Synthetic opioids, Fentanyl crisis

Fentanyl was originally synthesized in the 1960s as a medical opioid for severe pain and anesthesia, but today its illicit form dominates the U.S. opioid supply. Its extreme potency means that a lethal dose can be as little as two milligrams, making it highly dangerous. Because fentanyl is synthetically produced, there are no crop or seasonal limitations, allowing for year-round manufacture. The low cost of production means millions of doses can be created from just a few kilograms of precursor chemicals. Additionally, its easy distribution—tiny quantities can be shipped in envelopes, vehicles, or mail—makes it especially attractive to traffickers and difficult for authorities to intercept.

Fentanyl distribution methods, U.S. opioid supply, International drug control, Law enforcement fentanyl, Overdose antidotes, Regulatory incentives for industry, Biotech innovation overdose, Chemical industry fentanyl, Corporate responsibility opioids, Public health and opioids, Addiction treatment strategies, Financial targeting drug cartels, Supply-chain disruption, Precursor chemicals, Drug cartels, Weapons of mass destruction, Fentanyl trafficking, Federal response to fentanyl, Opioid epidemic, Synthetic opioids, Fentanyl crisis
From Engagement to Evidence: Building a Holistic Measure of Patient-Focused Drug Development
PatientCentricity, MeasuringImpact, PatientAdvocacy, HealthPolicy, PFDD, PatientOutcomes, ClinicalResearch, PatientEngagement, PatientFocused, HealthcareInnovation
From Engagement to Evidence: Building a Holistic Measure of Patient-Focused Drug Development
PatientCentricity, MeasuringImpact, PatientAdvocacy, HealthPolicy, PFDD, PatientOutcomes, ClinicalResearch, PatientEngagement, PatientFocused, HealthcareInnovation

While Patient-Focused Drug Development (PFDD) has elevated the patient voice in healthcare, significant gaps remain in translating these insights into measurable outcomes. True patient centricity goes beyond consultation—it requires embedding patient perspectives into every stage of drug development, from trial design to post-market evaluation. Yet, challenges persist: inconsistent patient engagement, lack of standardized metrics, and limited frameworks to assess the impact of patient input on decision-making. Measuring the success of patient-centric initiatives demands clear indicators, such as improvements in patient-reported outcomes, enhanced treatment adherence, and tangible changes in clinical or regulatory decisions. Only by identifying these gaps and establishing robust metrics can we ensure that patient-centered strategies deliver meaningful results rather than symbolic gestures.

PatientCentricity, MeasuringImpact, PatientAdvocacy, HealthPolicy, PFDD, PatientOutcomes, ClinicalResearch, PatientEngagement, PatientFocused, HealthcareInnovation
CON Laws and the ACA — The Next Frontier for Affordable Healthcare Reform
CON Laws and the ACA — The Next Frontier for Affordable Healthcare Reform

More than a decade after the Affordable Care Act expanded coverage for millions, a harsh reality remains: coverage does not equal access. Premiums continue to rise, rural care deserts are widening, and consolidated insurers and middlemen dominate every layer of the system. In this article, I explore the ACA’s most overlooked weakness—its failure to confront the structural barriers that suppress competition. From Certificate-of-Need laws to PBM pricing distortions and marketplace consolidation, these forces inflate costs and restrict care long before patients reach the exam room. To achieve true affordability and access, we must finish the job the ACA started by opening the system to innovation, transparency, and competition.

Read More
Monica Dudley-Weldon Monica Dudley-Weldon

Why We Must Treat Fentanyl as a Chemical Threat — and What Strategic Action Looks Like

Fentanyl has rightly been framed as a public health emergency. But that framing alone is no longer sufficient.

Illicit fentanyl now sits at the intersection of public health, national security, and chemical threat preparedness. Its extreme potency, ease of synthesis, and global availability create a dual-use risk that adversaries could exploit far beyond traditional drug trafficking. Former Department of Defense officials have already warned that terrorist groups may one day attempt to aerosolize fentanyl or its analogues—an alarming prospect with real historical precedent.

In 2002, an aerosolized fentanyl-based compound was used during the Moscow theater hostage crisis, killing more than 130 civilians. Today, similar compounds are more accessible, more potent, and embedded in illicit supply chains that span the globe. The question is no longer whether this risk exists—but whether our preparedness frameworks are aligned to confront it.

Treating fentanyl as a potential chemical threat does not criminalize medicine or undermine addiction treatment. It strengthens deterrence, improves readiness, and ensures that medical countermeasures, detection technologies, and defense doctrine keep pace with evolving threats.

Preparedness is not panic. It is policy maturity.

The full article outlines what strategic action looks like—from modernizing medical countermeasure development to investing in detection and deterrence technologies and leading international norms that close dangerous legal gaps.

Read More

Subscribe to our newsletter.

Sign up with your email address to receive news and updates.